Study 200 design

The efficacy and safety of BOSULIF as 2nd- and 3rd-line treatment were evaluated in a long-term follow-up1
The long-term analysis was based on a minimum of 60 months of follow-up for patients with CP CML treated with one prior TKI (imatinib) and a minimum of 48 months of follow-up for patients with CP CML treated with imatinib and at least 1 additional TKI (nilotinib and/or dasatinib).
BOSULIF was studied in 546 patients with Ph+ CML with resistance or intolerance to previous therapy1
BOSULIF was studied in a single-arm, Phase 1/2, open-label, multicenter trial in 546 patients with CP, AP, and BP CML who had developed resistance or intolerance to either 1st-line imatinib or 1st-line imatinib and then dasatinib and/or nilotinib.
Patients were treated with BOSULIF 500 mg once daily
Of the 546 treated patients, 506 were considered evaluable for efficacy. Patients were evaluable for efficacy if they had received at least 1 dose of BOSULIF and had a valid baseline efficacy assessment
AdvP=advanced phase; AP=accelerated phase; BP=blast phase; CHR=complete hematologic response; OHR=overall hematologic response; MCyR=major cytogenetic response; Ph+=Philadelphia chromosome–positive; TKI=tyrosine kinase inhibitor.
Reference
1.
BOSULIF Prescribing Information. New York, NY: Pfizer Inc.